Biomed-JR

Biomed-JR is a South Korean biotechnology company specializing in the development of next-generation Natural Killer (NK) cell therapies for the treatment of cancer. Founded in 2018 by CEO Joo-Ran Kim, the company leverages a proprietary platform for the high-purity expansion and activation of NK cells to enhance their anti-tumor efficacy and persistence. Its lead clinical candidate, BM-NK, is an autologous NK cell therapy currently undergoing Phase 1 clinical trials for patients with advanced solid tumors, including non-small cell lung cancer. Biomed-JR's research focuses on overcoming the immunosuppressive environment of solid tumors and developing off-the-shelf allogeneic cell products. The company is headquartered in Seongnam, South Korea, and has secured significant venture capital funding to advance its pipeline.